Significant Progress in Obesity and Ocular Programs Teleconference and Webcast to be held today - May 14, 2025 , at 11:00 AM EST CRANBURY, N.J. , May 14, 2025 /PRNewswire/ -- Palatin Technologies, Inc. (OTC PINK: PTNT), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system, today announced financial results for its fiscal third... Read More

Findings highlight PL9654 and PL9655's potential to treat diabetic retinopathy through inflammation resolution, vascular stabilization, and neuroprotection PL9654 and PL9655 down-regulate inflammatory pathways, suppress angiogenesis, and preserve retinal structure and function Topical and systemic administration options enable potential for earlier intervention than current therapies Results support the continued development... Read More

Company Transitioned onto the OTC Pink CRANBURY, N.J. , May 8, 2025 /PRNewswire/ -- Palatin Technologies, Inc . (OTC PINK: PTNT) ("Palatin" or the "Company"), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system, today announced the closing of a reduced previously announced public offering with participation from institutional and... Read More

Updated Phase 3 analysis highlights PL9643 as a potential first-in-class treatment achieving full symptom resolution. Responder analyses demonstrate statistically significant symptom resolution across multiple endpoints in PL9643-treated patients compared to placebo. 6 of 13 symptom endpoints reached statistical significance (p<0.05). This level of symptom clearing has not been demonstrated by any currently approved dry eye... Read More

The Company Intends to Request a Review of the Delisting Determination CRANBURY, N.J. , May 7, 2025 /PRNewswire/ -- Palatin Technologies, Inc. ( "Palatin" or the "Company"), a biopharmaceutical company developing first-in-class medicines targeting the melanocortin receptor system, today announced that it has received a notice from the NYSE American LLC ("NYSE American") stating that the NYSE Regulation has determined to... Read More

Funding Supports Advancement of Obesity Program and Strategic Business Development Initiatives Advancement of novel next-generation MC4R long-acting peptides and oral small molecules IND applications planned for Q4 2025; clinical data expected H1 2026 Phase 1 SAD/MAD studies to include patients with hypothalamic obesity Ocular asset collaborations expected in Q2 and Q3 2025 CRANBURY, N.J. , May 7, 2025 /PRNewswire/ --... Read More

$11.5 Million Upfront with up to an Additional $11.5 Million Upon the Cash Exercise of the Milestone Related Warrants CRANBURY, N.J. , May 7, 2025 /PRNewswire/ -- Palatin Technologies, Inc . (NYSE American: PTN) ("Palatin" or the "Company"), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system, today announced the pricing of its... Read More

Topical melanocortin therapy shows promise for treating glaucoma PL9588 lowers intraocular pressure (IOP) by increasing aqueous outflow Demonstrates neuroprotection independent of IOP reduction Supports continued development of PL9588 as a novel, dual-action glaucoma therapy CRANBURY, N.J. , May 5, 2025 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company advancing innovative... Read More

Updated Phase 3 analyses position PL9643 as a potential first-in-class therapy achieving full symptom resolution in dry eye disease. Responder analyses demonstrated statistically significant symptom clearing (resolution) across multiple endpoints in patients treated with PL9643, compared to placebo. Six of 13 symptom endpoints showed a significantly higher percentage of patients in the PL9643 group achieving complete symptom... Read More

Co-administered bremelanotide + tirzepatide, bremelanotide alone, and tirzepatide alone arms showed improvement in appetite suppression, fullness, and satiety Bremelanotide matched or exceeded tirzepatide in appetite suppression Low-dose bremelanotide helped prevent appetite rebound after tirzepatide cessation CRANBURY, N.J. , April 17, 2025 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical... Read More

Company working aggressively to regain compliance Common stock to continue to trade on NYSE American during the appeal process CRANBURY, N.J. , April 14, 2025 /PRNewswire/ -- Palatin Technologies, Inc. (the "Company") (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system, announced today that it has formally... Read More

CRANBURY, N.J. , April 10, 2025 /PRNewswire/ -- Palatin Technologies, Inc. (the "Company") (NYSE American:PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system, announced today that on April 10, 2024 , NYSE American LLC ("NYSE American") publicly announced and provided a notice to the Company that NYSE Regulation has determined... Read More

Six-month open-label study showed clinically meaningful improvements in kidney function and disease in patients with Type 2 diabetic nephropathy. 71% achieved a >30% reduction in UP/Cr, a key indicator of kidney damage. 71% demonstrated improved or stabilized eGFR, signaling preserved kidney function. 37.5% had increased urinary VEGF levels, suggesting better blood vessel support in the kidneys. 36% had reduced urinary... Read More

Primary endpoint met in the 8-week treatment study (highly statistically significant). Co-administered group had a 4.4% reduction in weight compared to 1.6% for the placebo group (p<0.0001). Primary analysis for the co-administered group in the 8-week treatment study showed: 40% of patients achieved 5% reduction in weight (p<0.05). 27% achieved 6% reduction in weight (p<0.05). 19% achieved 7% reduction in weight (p<0.1). Low... Read More

Clinical Remission: Achieved in 33% of PL8177-treated patients versus 0% on placebo after eight weeks of treatment. Clinical Response (statistically significant): Demonstrated in 78% of PL8177-treated patients versus 33% on placebo after eight weeks of treatment (p<0.005). Symptomatic Remission: Achieved in 56% of PL8177-treated patients versus 33% on placebo after eight weeks of treatment. Safety and Tolerability:... Read More

Initiated IND-enabling toxicology program IND submission planned for 4Q25; Clinical data expected in 1H26 CRANBURY, N.J. , March 25, 2025 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system, today announced the US Food & Drug Administration (FDA) has granted "orphan... Read More

Phase 2 obesity co-administration study with MC4R agonist bremelanotide plus GLP-1/GIP dual agonist tirzepatide Database lock completed Topline data readout expected later this month Novel 'next generation' selective MC4R long-acting peptide and an oral small molecule Multiple clinical trials targeted in calendar year 2025 For the treatment of general obesity, weight loss management, and rare MC4R pathway diseases, including... Read More

CRANBURY, N.J. , Feb. 10, 2025 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN) will announce its second quarter fiscal year 2025 operating results on Thursday, February 13, 2025 , before the open of the U.S. financial markets. Palatin will also conduct a conference call and live audio webcast hosted by its executive management team on February 13, 2025 , at 11:00 a.m. ET . The conference call will include a... Read More

CRANBURY, N.J. , Feb. 7, 2025 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN) ("Palatin" or the "Company"), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system, today announced that it has entered into definitive agreements with a single healthcare focused institutional investor for the purchase and sale of 4,688,000... Read More

Last Patient / Last Visit Completed Topline Data Readout Expected Later This Quarter CRANBURY, N.J. , Feb. 6, 2025 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system, today announced the completion of its Phase 2 BMT-801 clinical study of the co-administration of MC4R... Read More

Obesity programs: Phase 2 BMT-801 clinical study with MC4R agonist bremelanotide plus GLP-1/GIP dual agonist tirzepatide Topline results expected 1Q calendar year 2025 General obesity, weight loss management, and rare neuroendocrine and genetic diseases, including hypothalamic obesity Multiple clinical trials targeted to commence 2H calendar year 2025 with long-acting MC4R peptide and/or MC4R oral small molecule compounds... Read More

Open label study designed to evaluate the safety, tolerability, and efficacy of bremelanotide in patients with Type 2 diabetic nephropathy Demonstrated efficacy at 6 months 71% percent of patients achieved a >30% reduction in the urine protein to creatinine ratio (UP/Cr) 71% of patients achieved improved or stabilized estimated glomerular filtration rate (eGFR) Bremelanotide therapy increased urinary VEGF levels in 37.5% of... Read More

CRANBURY, N.J. , Dec. 16, 2024 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN) ("Palatin" or the "Company"), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system, today announced that it has entered into a warrant exercise inducement agreement (the "inducement agreement") with an institutional investor to exercise... Read More

Oral PL8177 may provide a safe, effective, and tolerable treatment option for ulcerative colitis patients prior to immunosuppressive therapies and steroid treatments, which have significant safety and tolerability concerns Preclinical data demonstrated that oral PL8177 caused diseased colons to move towards a healthy state and to resolve damaging inflammation Data expected 1Q calendar year 2025 CRANBURY, N.J. , Nov. 25, 2024... Read More

Obesity programs: Core focus on obesity includes exploratory co-administration BMT-801 study and two novel development drug candidates Phase 2 BMT-801 clinical study with MC4R agonist bremelanotide plus GLP-1/GIP dual agonist tirzepatide Patient enrollment completed October 2024 Topline results expected 1Q calendar year 2025 Multiple clinical trials targeted in calendar year 2025 with long-acting MC4R peptide and oral small... Read More

CRANBURY, N.J. , Nov. 8, 2024 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN) will announce its first quarter fiscal year 2025 operating results on Thursday, November 14, 2024 , before the open of the U.S. financial markets. Palatin will also conduct a conference call and live audio webcast hosted by its executive management team on November 14, 2024 , at 11:00 a.m. ET . The conference call will include a... Read More

Oral PL7737 significantly decreased food intake and body weight Oral small molecule melanocortin 4 agonist (MC4R) could address unmet needs and challenges of current obesity treatments Multiple clinical trials targeted in calendar year 2025 for the Company's obesity programs CRANBURY, N.J. , Nov. 4, 2024 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class... Read More

Topline results expected in 1Q calendar year 2025 Study is assessing the co-administration of bremelanotide and tirzepatide on reducing body weight Data will inform and support the Company's obesity programs using novel, long-acting and highly selective MC4R peptide and small molecule compounds for treating general obesity, weight loss management, and rare/orphan MC4R pathway diseases, including hypothalamic obesity... Read More

Data presented from clinical and preclinical studies Melanocortin agonism reduces stress signaling and resolves inflammation Potential to treat inflammatory diseases without immunosuppression CRANBURY, N.J. , Oct. 24, 2024 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor... Read More

High selectivity for MC4R significantly reduces potential for skin pigmentation MC4R is a well-validated target for treating obesity Clinical studies with highly selective MC4R agonists targeted to commence in calendar year 2025 CRANBURY, N.J. , Oct. 23, 2024 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the... Read More

CRANBURY, N.J. , Oct. 7, 2024 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system, today announced it received a notice from the staff of NYSE American LLC (the "Exchange") that Palatin was not in compliance with the Exchange's continued listing standards under Section... Read More

Obesity: Phase 2 Clinical Study with Melanocortin-4 Receptor (MC4R) Agonist plus Glucagon Like Peptide-1 (GLP-1) Patient Dosing Commenced 3Q Calendar Year 2024 Patient Enrollment Expected to be Completed Early 4Q Calendar Year 2024 Topline Results Expected 1Q Calendar Year 2025 Dry Eye Disease (DED): PL9643 MELODY-2 & MELODY-3 Phase 3 Pivotal Clinical Studies FDA Confirms Protocols and Endpoints Patient Enrollment Start... Read More

Teleconference and Webcast to be held on October 1, 2024 CRANBURY, N.J. , Sept. 26, 2024 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN) will announce its fourth quarter and fiscal year end 2024 operating results on Tuesday, October 1, 2024 , before the open of the U.S. financial markets. Palatin will also conduct a conference call and live audio webcast hosted by its executive management team on October 1,... Read More

Dry Eye Disease (DED): PL9643 MELODY-2 & MELODY-3 Phase 3 Pivotal Clinical Studies FDA Confirms Protocols and Endpoints Targeting Enrollment Start in 4Q Calendar Year 2024 Topline Results Anticipated 4Q Calendar Year 2025 Potential Collaboration/Funding Discussions Ongoing Obesity: Phase 2 Clinical Study with Melanocortin-4 Receptor (MC4R) Agonist + Glucagon Like Peptide-1 (GLP-1) Patient Dosing Commenced 3Q Calendar Year... Read More

FDA & Palatin agree on clear regulatory path for PL9643 NDA submission in DED FDA confirms acceptability of protocols and endpoints for remaining MELODY-2 & MELODY-3 Phase 3 Pivotal Clinical Trials in DED Currently anticipate patient enrollment to start in 4Q calendar year 2024 Topline results currently expected in 4Q calendar year 2025 CRANBURY, N.J. , Aug. 28, 2024 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American:... Read More

Complete enrollment currently expected in 3Q 2024 Topline results expected in 1Q calendar year 2025 Additional studies under assessment for multiple metabolic conditions CRANBURY, N.J. , Aug. 22, 2024 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system, today announced... Read More

CRANBURY, N.J. , June 21, 2024 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN) ("Palatin" or the "Company"), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system, today announced that it has entered into a warrant inducement agreement with an institutional investor to exercise certain outstanding warrants that the... Read More

In ED patients that do not respond to PDE5i monotherapy ~30-40% of ED patients do not respond to PDE5i treatment Data from this Phase 2 clinical study is expected by end of calendar year 2024 Published clinical data and mechanisms of action support clinical study of bremelanotide in combination with a PDE5i Phase 3 clinical study with new co-formulated bremelanotide plus a PDE5i in ED patients that do not respond to PDE5i... Read More

Co-Administration Phase 2 study of bremelanotide with tirzepatide (GLP-1) to provide key information for melanocortin treatments of obesity Topline data expected by end of calendar year 2024 Additional studies under assessment for multiple metabolic conditions CRANBURY, N.J. , June 12, 2024 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based... Read More

Positive Phase 3 PL9643 MELODY-1 Pivotal Study Results Co-Primary Symptom Endpoint of Pain Met Statistical Significance (P<0.025) and 7 of 11 Secondary Symptom Endpoints Met Statistical Significance (P<0.05), at the12-Week Treatment Period Rapid Onset of Efficacy and Multiple Symptom Endpoints, Including the Co-Primary Pain Endpoint, Met Statistical Significance (P<0.05) at the 2-Week Treatment Period and Continued to... Read More

CRANBURY, N.J. , May 9, 2024 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN) will announce its third quarter fiscal year 2024 operating results on Wednesday, May 15, 2024 , before the open of the U.S. financial markets. Palatin will also conduct a conference call and live audio webcast hosted by its executive management team on May 15, 2024 , at 11:00 a.m. ET . The conference call will include a review of the... Read More

Phase 2 clinical study expected to begin in mid-calendar year 2024 Topline data expected by calendar year-end 2024 Hosting virtual KOL event "Beyond GLPs" on May 8, 2024 Focus will be on Company's metabolic program and the multiple roles for novel melanocortin receptor 4 agonists in treating obesity and weight loss maintenance CRANBURY, N.J. , May 2, 2024 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN), a... Read More

CRANBURY, N.J. , April 30, 2024 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system, today announced it will host a virtual KOL event on Wednesday, May 8, 2024 at 10:00 AM ET . To register, click here. The event will feature Jesse Richards , DO ( Oklahoma State... Read More

Positive Phase 3 Study Results Included in Dr. Eric Donnenfeld's Presentation Co-Primary Symptom Endpoint of Pain Met Statistical Significance (P<0.025) and 7 of 11 Secondary Symptom Endpoints Met Statistical Significance (P<0.05), 12-Week Treatment Period Rapid Onset of Efficacy at the 2-Week Treatment Period, Multiple Symptom Endpoints, Including the Co-Primary Pain Endpoint, Met Statistical Significance and Continued to... Read More

On an Intent-to-Treat Analysis, Co-Primary Symptom Endpoint Met, Statistical Significance (P<0.025) Multiple Secondary Symptom Endpoints Met, Statistical Significance (P<0.025) On an Intent-to-Treat Analysis, Co-Primary Sign Endpoint and Secondary Sign Endpoints Not Met PL9643 Demonstrated Superiority Over Vehicle in Multiple Sign Endpoints Excellent Safety and Tolerability Profile Future Discussions Planned with FDA... Read More

Palatin's Focus is Solely on the Development of its Melanocortin Receptor (MCR) System Pipeline PL9643 MELODY-1 Pivotal Phase 3 Study in Dry Eye Disease (DED) – Topline Data Expected in February Oral PL8177 Phase 2 Clinical Study in Patients with Ulcerative Colitis – Interim Analysis Expected in 2Q Calendar Year 2024 – Topline Results Expected in 2H Calendar Year 2024 BMT 701 Phase 2 BREAKOUT study in patients with diabetic... Read More

CRANBURY, N.J. , Feb. 9, 2024 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN) will announce its second quarter fiscal year 2024 operating results on Thursday, February 15, 2024 , before the open of the U.S. financial markets. Palatin will also conduct a conference call and live audio webcast hosted by its executive management team on February 15, 2024 , at 11:00 a.m. ET . The conference call will include a... Read More

Top-Line Results Expected in February CRANBURY, N.J. , Feb. 5, 2024 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system, today announced database lock for its PL9643 MELODY-1 pivotal Phase 3 clinical trial evaluating the safety and efficacy of PL9643 versus vehicle in... Read More

CRANBURY, N.J. , Feb. 1, 2024 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN) ("Palatin" or the "Company"), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system, today announced the closing of its previously announced registered direct offering of 1,831,503 shares of its common stock, at a purchase price of $5.46 per... Read More

CRANBURY, N.J. , Jan. 30, 2024 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN) ("Palatin" or the "Company"), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system, today announced that it has entered into a definitive agreement with healthcare-focused institutional investors for the issuance and sale of an aggregate of... Read More

Dry Eye Disease (DED): PL9643 MELODY-1 Phase 3 Study Data Base Lock 2H January 2024 Topline Data Readout Expected Early 1Q Calendar Year 2024 Ulcerative Colitis (UC): Oral PL8177 Phase 2 Clinical Study in Active UC Patients Interim Analysis Data Readout on Track for 1Q Calendar Year 2024 Topline Results Expected in 2Q Calendar Year 2024 Obesity: Melanocortin Receptor 4 (MCR4) Agonist + Glucagon Like Peptide-1 (GLP-1) Phase 2... Read More

Palatin to receive $12 million upfront, plus sales-based milestones of up to $159 million Palatin's focus is solely on its development and clinical pipeline based on the melanocortin receptor system CRANBURY, N.J. , Dec. 20, 2023 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin... Read More

CRANBURY, N.J. , Dec. 18, 2023 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system, today announced it received a notice from the staff of NYSE American LLC (the "Exchange") approving Palatin's plan (the "Plan") to come into compliance with the Exchange's continued... Read More

Enrollment Complete in Phase 3 PL9643 MELODY-1 Study in Dry Eye Disease (DED) 570 Patients Enrolled Topline Data Currently Expected Late 4Q Calendar Year 2023 Phase 2 Clinical Study of Oral PL8177 in Patients with Ulcerative Colitis Interim Analysis Targeted for 1Q Calendar Year 2024 Topline Results Currently Expected in 2Q Calendar Year 2024 Vyleesi ® Gross Product Revenue Increased 11% Over the Prior Quarter Net Product... Read More

CRANBURY, N.J. , Nov. 9, 2023 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN) will announce its first quarter fiscal year 2024 operating results on Tuesday, November 14, 2023 , before the open of the U.S. financial markets. Palatin will also conduct a conference call and live audio webcast hosted by its executive management team on November 14, 2023 , at 11:00 a.m. ET . The conference call will include a... Read More

CRANBURY, N.J. , Oct. 24, 2023 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN) ("Palatin" or the "Company"), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system, today announced the closing of its previously announced registered direct offering of 2,358,491 shares of its common stock (or common stock equivalents in... Read More

CRANBURY, N.J. , Oct. 23, 2023 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN) ("Palatin" or the "Company"), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system, today announced that it has entered into a definitive agreement with an institutional investor for the issuance and sale of an aggregate of 2,358,491 shares... Read More

7 Consecutive Quarters of Double-Digit Growth in Product Revenue and Prescriptions Dispensed $4.6 million in Gross Product Revenue 11% growth over prior quarter; 100% growth over comparable quarter last year $2.1 million in Net Product Revenue 18% growth over prior quarter; 137% growth over comparable quarter last year Prescriptions Dispensed 14% growth over prior quarter; 88% growth over comparable quarter last year... Read More

Positive data with Palatin's melanocortin-4 receptor (MC4R) agonist plus glucagon like peptide-1 (GLP-1) presented at the Peptide Therapeutics Symposium GLP-1 & MC4R agonist co-administration data shows increased weight loss and greater glucose control above monotherapy Preclinical data and prior clinical studies support the further clinical development and commercial potential of Palatin's melanocortin agonists for obesity... Read More

Data demonstrates oral PL8177 causes diseased colons to move to a healthier state Provides further support for ongoing oral PL8177 Phase 2 ulcerative colitis study CRANBURY, N.J. , Oct. 16, 2023 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system, today announced the... Read More

Palatin to Deliver Plan of Compliance to NYSE American CRANBURY, N.J. , Oct. 13, 2023 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system, today announced it received a notice from the staff of NYSE American LLC (the "Exchange") that Palatin was not in compliance with... Read More

Enrollment in Phase 3 PL9643 MELODY-1 Study in Dry Eye Disease (DED) is Complete with 570 Patients Enrolled Topline Data Expected Late 4Q Calendar Year 2023 Interim Analysis of Initial 120 Patients Showed Statistical Separation for Clinical Efficacy Across Multiple Signs and Symptoms of Dry Eye Excellent Patient Safety and Tolerability Product Profile Phase 2 Clinical Study of Oral PL8177 in Patients with Ulcerative Colitis... Read More

CRANBURY, N.J. , Sept. 22, 2023 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN) will announce its fourth quarter and fiscal year end 2023 operating results on Thursday, September 28, 2023 , before the open of the U.S. financial markets. Palatin will also conduct a conference call and live audio webcast hosted by its executive management team on September 28, 2023 , at 11:00 a.m. ET . The conference call will... Read More

CRANBURY, N.J. , Sept. 7, 2023 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system, today announced that management will present at H.C. Wainwright 25 th Annual Global Investment Conference taking place September 11-13, 2023 in New York, NY . The Company presentation... Read More

Topline data currently expected late 4Q calendar 2023 Interim analysis of first 120 patients demonstrated: Excellent safety and tolerability product profile Potential for PL9643 to address multiple signs and symptoms of dry eye disease CRANBURY, N.J. , Sept. 7, 2023 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate... Read More

~30-40% of ED patients do not respond to PDE5i treatment Published clinical data and mechanisms of action support clinical study of bremelanotide in combination with a PDE5i Successfully co-formulated bremelanotide with a PDE5i Phase 2 clinical study in PDE5i non-responder ED patients currently expected to commence in 4Q 2023 CRANBURY, N.J. , Aug. 10, 2023 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN), a... Read More

First prescription dispensed in Chinese Hainan Province 93% of patients enrolled completed the Phase 3 trial in premenopausal patients with Hypoactive Sexual Desire Disorder (HSDD) in South Korea Data expected later this year Supports submission to Korean Ministry of Food & Drug Safety (MFDS) for Marketing Approval CRANBURY, N.J. , Aug. 8, 2023 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN), a... Read More

Partnership will increase hypoactive sexual desire disorder (HSDD) awareness and expand access to Vyleesi via UpScriptHealth's Women's Health Platform CRANBURY, N.J. , Aug. 7, 2023 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system, today announced that it has entered... Read More

CRANBURY, N.J. , Aug. 4, 2023 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system, today announced that management will participate at the Canaccord Genuity 43 rd Annual Growth Conference on Wednesday, August 9, 2023 at 5:00 p.m. ET in an Analyst led Fireside Chat. A... Read More

$4.1 million in Gross Product Revenue 20% growth over 3Q23; 78% growth over 4Q22 $1.7 million in Net Product Revenue 42% growth over 3Q23; 122% growth over 4Q22 14% growth in prescriptions dispensed over 3Q23; 89% growth over 4Q22 6 consecutive quarters of double-digit growth 20% growth in new healthcare prescribers over 3Q23 CRANBURY, N.J. , July 11, 2023 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN), a... Read More

Results demonstrate melanocortin agonists may represent a new therapeutic avenue to treat diabetic nephropathy Open Label Phase 2 clinical study in diabetic kidney disease enrolling patients CRANBURY, N.J. , May 30, 2023 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor... Read More

Phase 3 PL9643 Data in Patients with Dry Eye Disease Presented at KOL Event Analysis of Lead-In Population of Initial 120 Patients Showed Statistical Separation for Clinical Efficacy Across Multiple Signs and Symptoms of Dry Eye along with Excellent Patient Safety and Tolerability Final Data Expected Second Half Calendar Year 2023 Phase 2 Clinical Study of Oral PL8177 in Patients with Ulcerative Colitis Interim Analysis... Read More

CRANBURY, N.J. , May 11, 2023 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN) will announce its third quarter fiscal year 2023 operating results on Tuesday, May 16, 2023 , before the open of the U.S. financial markets. Palatin will also conduct a conference call and live audio webcast hosted by its executive... Read More

Preclinical data presented shows PL8177 was found to be efficacious in animal models of inflammatory bowel disease Clinical data confirms PL8177 oral formulation is delivered and contained in the colon Phase 2 clinical study data readout in 2H2023 CRANBURY, N.J. , May 9, 2023 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules... Read More

CRANBURY, N.J. , May 8, 2023 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system, today hosted a key opinion leader (KOL) webinar presenting data from the Lead-In population of the ongoing PL9643 MELODY-1 Phase 3 clinical trial for Dry Eye Disease. The webinar was... Read More

Review of Phase 3 PL9643 Data for Dry Eye Disease Data demonstrates PL9643 positive effects on signs and symptoms of dry eye disease Webinar to take place on Monday, May 8, 2023 at 11:00 AM ET CRANBURY, N.J. , May 1, 2023 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor... Read More

Poster data demonstrates PL9643 positive effects on signs and symptoms of dry eye disease Consistent clinical efficacy across multiple signs and symptoms of dry eye along with excellent safety and tolerability build a differentiating product profile Melody-1 Phase 3 clinical study continuing patient enrollment - final data second half of 2023 CRANBURY, N.J. , April 27, 2023 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE... Read More

Poster presented at ARVO demonstrates PL9588 reduces intraocular pressure Data provides further support for topical administration of melanocortins for ocular inflammation CRANBURY, N.J. , April 25, 2023 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system, today... Read More

$3.4 million in Gross Product Revenue 31% growth over 2Q23; 165% growth over 3Q22 $1.2 million in Net Product Revenue 22% growth over 2Q23; 469% growth over 3Q22 27% growth in prescriptions dispensed over 2Q23; 147% growth over 3Q22 5 consecutive quarters of double-digit growth CRANBURY, N.J. , April 19, 2023 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing... Read More

International Journal of Molecular Sciences manuscript demonstrates robust pre-clinical data in two retinal disease models Studies further demonstrate broad utility of melanocortin agonists in treating inflammatory conditions, especially in the eye CRANBURY, N.J. , April 18, 2023 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules... Read More

Oral PL8177 is gut restricted in rats, dogs and humans Bioinformatics data shows positive effects on enterocytes and infiltrating immune cells CRANBURY, N.J. , March 2, 2023 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system, today announced Frontiers in Immunology... Read More

CRANBURY, N.J. , Feb. 28, 2023 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system, announced that the United States Patent and Trademark Office issued U.S. Patent No. 11,590,209, titled "Use of Bremelanotide in Patients with Controlled Hypertension." This issued... Read More

Phase 3 Pivotal Study of PL9643 in Patients with Dry Eye Disease Ongoing Patient Enrollment on Track Topline Results Currently Expected Mid-Calendar Year 2023 Phase 2 Clinical Study of Oral PL8177 in Patients with Ulcerative Colitis Commenced First Patient Dosed Planned Interim Analysis Targeted for First Half Calendar Year 2023 Topline Results Currently Expected Second Half Calendar Year 2023 Phase 2 Clinical Study of... Read More

CRANBURY, N.J. , Feb. 10, 2023 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN) will announce its second quarter fiscal year 2023 operating results on Wednesday, February 15, 2023 , before the open of the U.S. financial markets. Palatin will also conduct a conference call and live audio webcast hosted by its executive management team on February 15, 2023 , at 11:00 a.m. ET . The conference call will include a... Read More

BREAKOUT Study is Palatin's third clinical program for the potential treatment of inflammatory diseases with melanocortin agonists Primary endpoint of the BREAKOUT Study is a 50% reduction in urine protein/creatinine (UP/Cr) ratio after six months of combined therapy (RAAS inhibition therapy plus bremelanotide) CRANBURY, N.J. , Jan. 19, 2023 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical... Read More

Sells Net Operating Loss Tax Benefits Through New Jersey Economic Development Program CRANBURY, N.J. , Jan. 18, 2023 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system, today announced it has received approximately $4.7 million of non-dilutive funding through the New... Read More

Collaboration with The William Harvey Research Institute and Queen Mary University of London PL-8177 displayed pro-resolving and anti-arthritic effects in rodents CRANBURY, N.J. , Jan. 10, 2023 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system, today announced... Read More

15.4% increase in net product revenue over the prior quarter 1,290% increase over the comparable quarter in 2021 11.5% increase in prescriptions dispensed over the prior quarter Increased 134% over the comparable quarter in 2021 CRANBURY, N.J. , January 5, 2023 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the... Read More